Phase 3
Completed N=1,262
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Source: ClinicalTrials.gov NCT01436149 ↗Enrolled (actual)
1,262
Serious AEs
2.0%
Results posted
Nov 2014
Primary outcomePrimary: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks — -6.3; -6.1 units on a scale — p=0.883
Summary
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:
* How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?
* Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant?
* How much SPD489 should be given to patients with depression who are also taking an antidepressant?
* How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks |
-6.3; -6.1 | 0.883 |
| SECONDARY Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks |
-4.3; -4.7 | 0.576 |
| SECONDARY Percentage of Participants Achieving a 25% Response on the MADRS |
65.0; 74.5 | — |
| SECONDARY Percentage of Participants Achieving a 50% Response on the MADRS |
38.5; 41.0 | — |
| SECONDARY Percentage of Participants Achieving Remission on the MADRS |
22.5; 18.5 | — |
| SECONDARY Mean Change From Baseline Over Time in MADRS Total Score |
-2.2; -3.4; -3.8; -4.2; -6.0; -5.4 | — |
| SECONDARY Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR) |
-2.6; -2.3 | — |
| SECONDARY Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2) |
0.69; -0.81; 5.59; 6.5 | — |
| SECONDARY Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF) |
7.2; 7.0 | — |
| SECONDARY Clinical Global Impressions - Global Improvement (CGI-I) |
53.3; 55.3; 46.2; 44.7; 0.5; 0 | — |
| SECONDARY Columbia Suicide Severity Rating Scale (C-SSRS) |
7.0; 7.0; 0.5; 0 | — |
| SECONDARY Amphetamine Cessation Symptom Assessment (ACSA) |
15.1; 14.7 | — |
Eligibility Criteria
Inclusion Criteria
- Subject is able to provide written, personally signed, and dated informed consent to participate in the study.
- Subject is between 18 and 65 years of age.
- Subject has a primary diagnosis of non-psychotic MDD (single or recurrent).
- Subject has a MADRS total score 24.
- Subject who is female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test at the and agrees to comply with any applicable contraceptive requirements of the protocol.
- Subject is able to swallow a capsule.
Exclusion Criteria
- Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents.
- Subject who has a lifetime history of treatment resistant depression.
- Subject has a current co-morbid psychiatric disorder. Excluded are: any significant Axis II disorder (including borderline personality disorder), any bipolar disorder, any current or lifetime psychosis, post traumatic stress disorder, obsessive compulsive disorder, any pervasive development disorder, anorexia nervosa and bulimia nervosa.
- Subject has been hospitalized (within the last 12 months) for their current MDD episode.
- Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).
- Subject has a first degree relative that has been diagnosed with bipolar I disorder.
- Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder
- Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.
- Subject has a concurrent chronic or acute illness or unstable medical condition.
- Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.
- Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
- Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.
- Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
- Subject has glaucoma.
- Subject has a history of moderate to severe hypertension.
- Current use of any other medications (including over-the-counter [OTC], herbal or homeopathic preparations) that have central nervous system effects.
- Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior.
- The subject has a known or suspected intolerance, hypersensitivity, or contraindications to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl).
- Subject has a positive urine drug result.
- Subject has a body mass index (BMI) of 40.
- Subject is female and is pregnant or nursing.
Data sourced from ClinicalTrials.gov (NCT01436149). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.